Cutaneous leishmaniasis of the face treated with imiquimod 3.75.

Enferm Infecc Microbiol Clin (Engl Ed)

Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, España. Electronic address:

Published: February 2021

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eimc.2020.04.005DOI Listing

Publication Analysis

Top Keywords

cutaneous leishmaniasis
4
leishmaniasis face
4
face treated
4
treated imiquimod
4
imiquimod 375
4
cutaneous
1
face
1
treated
1
imiquimod
1
0
1

Similar Publications

Layşmanyaz, yaklaşık 90'dan fazla ülke ve bölgeden bildirilen, ciddi ve endemik bir bulaşıcı hastalıktır. Kutanöz layşmanyaz (KL) ise vücudun açıkta kalan bölgelerinde oluşan, başlıca semptomları arasında vektör Phlebotomus ısırığından altı ay sonra kronikleşebilen veya kendiliğinden iyileşebilen ciltte tek, birden fazla ülserli veya nodüler lezyonlar bulunan, ölümcül olmayan ancak kalıcı izler bırakabilen bir hastalıktır. Klasik tedavi yöntemleri, uygulamada zorluk, direnç gelişimi ve yan etki gibi bir dizi soruna neden olmaktadır.

View Article and Find Full Text PDF

Background: Anthrax is a life-threatening zoonotic disease caused by Gram-positive, spore-forming bacterium . It manifests as a cutaneous, gastrointestinal, and respiratory disease. The cutaneous form ranges from a self-limiting lesion to severe edematous lesions with toxemic shock.

View Article and Find Full Text PDF

Visceral leishmaniasis (VL) is a vector-borne disease caused by the obligate intracellular protozoan in India. VL can be complicated by post-kala-azar dermal leishmaniasis (PKDL), a macular or nodular rash that develops in 10%-20% of patients after treatment of VL in India. Patients with PKDL are infectious to sand flies, promoting further transmission of the parasite.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!